Latest Organofluorides Stories
Pharmacokinetics, Safety and Tolerability of NVR-1221 Support Advancement to Phase 1b Clinical Studies in Patients with Chronic HBV Infection DOYLESTOWN, Pa., Sept.
Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market SAN ANTONIO, Sept.
AUSTIN, Texas, Sept.
The Firm is evaluating potential Lipitor lawsuits on behalf of individuals who allegedly developed Lipitor diabetes injuries after taking the cholesterol-lowering statin drug. New
Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY
DUBLIN, Ireland, August 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/ljjdcg/global) has announced the addition of the "Global
ReportsnReports.com adds “2014 Market Research Report on Global and China Trifluoroacetic Acid Industry” market research report to its store. Dallas, TX
The Firm is actively filing Risperdal lawsuits on behalf of men and boys who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication.
Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information.
- A small wooded valley; a dell.
- The protecting weather-shed built around the entrance to a house.